Combined surgery and HIPEC treatment for peritoneal carcinomatosis,

Combined treatment of surgery and HIPEC for peritoneal carcinomatosis

Written by: Dr. Juan José Torrent Correa
Published: | Updated: 13/08/2018
Edited by: Top Doctors®

Treatment of patients with peritoneal carcinomatosis has evolved greatly in the last 20 years. Peritoneal carcinomatosis (PC), also known as peritoneal carcinomatosis, refers to tumor spread or spread of cancer to nearby organs.

peritoneal carcinomatosis surgery Peritoneal carcinomatosis may have two origins: first, the peritoneum (pseudomyxoma and mesothelioma) and, secondly, an origin in tumors related to the digestive system or the Gynecology .

 

Treatment of peritoneal carcinomatosis

The treatment of peritoneal carcinomatosis combines debulking surgery and HIPEC which is intraperitoneal hyperthermal chemotherapy. Before using this combined treatment, peritoneal carcinomatosis was considered a terminal stage with a median survival of 20 months in cases of gastrointestinal origin.

Thanks to improvements in surgical techniques used and management protocols safer chemotherapy, complications associated with treatment has decreased. This has caused the median survival in cases of gastrointestinal origin increased to 60 months.

One of the most important factors for the expansion of this combination treatment for peritoneal carcinomatosis is the learning curve. The mortality can be reduced by 50% and morbidity of 30%, a figure that can be compared with any digestive surgery such as a pancreatectomy. The learning curve includes the correct selection of patients for such a complex treatment.

*Translated with Google translator. We apologize for any imperfection

By Dr. Juan José Torrent Correa
Obstetrics & Gynecology

Founder of the JTI Surgical Oncology in Barcelona, ​​Dr. Torrent is an expert in minimally invasive oncological surgery (laparoscopy), a disciple of Professor Chapron, Hopital Cochin, of Paris. His professional activity began at the Institut Claudius Regaud (Toulouse), with Pr. Querleu, and, currently, he collaborates with the team of Dr. Françoise Quénet at the Institut du Cancer de Montpellier (ICM). His area of ​​specialization focuses on the surgical treatment of peritoneal carcinomatosis of ovarian origin and participates as a researcher in European clinical studies on peritoneal carcinomatosis, cytoreduction surgery and HIPEC.

*Translated with Google translator. We apologize for any imperfection

View Profile

Overall assessment of their patients


TOPDOCTORS utiliza cookies propias y de terceros para facilitar su experiencia como usuario de nuestra web y captar datos estadísticos mediante el análisis de sus datos de navegación. Si usted continúa con la navegación, entendemos que nos ofrece su consentimiento para el uso de cookies. Puede cambiar la configuración de cookies u obtener más información here.